Navigation Links
Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database

PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a review validating the utility of its ProChart(TM) database to help define the function of the WW domain-containing oxidoreductase (WWOX), an important tumor suppressor gene with known involvement in breast, prostate, lung, pancreatic, esophageal, and gastric cancers. The peer-reviewed article was published in the online edition (25 April 2007) of the Journal of Cellular Physiology as a Mini Review entitled "WWOX in biological control and tumorigenesis," by Rami I. Aqeilan and Carlo M. Croce, epub 25 April 2007. The publication focuses on the most recent progress in understanding the function of WWOX as a tumor suppressor.

WW and other modular domain families are known to be important in mediating many important protein-protein interactions. Because WWOX contains two WW domains, it was an ideal protein to analyze with ProChart, Cytogen's proprietary, comprehensive, experimentally validated database of protein-protein signaling interactions. Using ProChart, the authors were able to determine a number of novel WWOX-interacting proteins, including the transcription factors p73 and Ap-2 gamma, the latter of which is known to play a role in activating the expression of the epidermal growth factor, HER2 (erbB-2). The study also reviews the importance of the relationships between WWOX and critical proto-oncogenes such as ErbB4 and c-Jun.

Using ProChart to accelerate their studies of WWOX, in recent years researchers from Ohio State University have validated a number of key WWOX interactions and published several peer-reviewed journal articles. Prior to the application of ProChart, little was known about the specific biologic functions of WWOX protein expression or the signaling pathways that lead to its tumor suppressive effects. In the current publication, the authors specifically refer to the usefulness of the ProChart data to help them define the WWOX pathway and its role in tumor suppression.

While Cytogen's internal research and development initiatives focus on clinical-stage opportunities, the Company complements its internal programs with an active business development strategy, which includes capitalizing on the promising proprietary technology platforms, such as ProChart, previously developed through its AxCell BioSciences research-stage subsidiary.

In view of recent biological validation, as well as the progress of internal data mining efforts and external research collaborations, Cytogen is exploring strategic transactions for AxCell BioSciences and will be presenting today at the 9th Annual C21 BioVentures Conference (C21) taking place in Monterey, California.

About ProChart(TM)

ProChart is a proprietary, comprehensive, experimentally validated database of protein-protein signaling interactions mediated by WW, SH3, PDZ, and other modular domain families. Cytogen believes the application of ProChart may accelerate research and drug development by: (i) discovering novel signal transduction pathways and their relevant protein-protein interactions; (ii) rapidly identifying qualified drug targets; (iii) identifying potential unwanted side effects; (iv) identifying structure and activity relationship (SAR) information regarding domain and ligand interactions that can facilitate small molecule drug design; and (v) providing high throughput screening reagents (eg, cloned domains and ligands).

About Cytogen

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets three therapeutic products and one diagnostic product to the U.S. oncology market. CAPHOSOL(R) is an advanced electrolyte solution for the treatment of oral mucositis and d ry mouth that is approved in the U.S. as a prescription medical device. QUADRAMET(R) (samarium Sm-153 lexidronam injection) is approved for the treatment of pain in patients whose cancer has spread to the bone. PROSTASCINT(R) (capromab pendetide) is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer and SOLTAMOX(TM) (tamoxifen citrate) is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy centers on attaining sustainable growth through clinical, commercial, and strategic initiatives.

A copy of the full prescribing information for CAPHOSOL, QUADRAMET, PROSTASCINT and SOLTAMOX, including Boxed Warnings, warnings, precautions, adverse events and other safety information may be obtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the web site at The Company's website is not part of this press release.

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. There are a number of important factors that could cause Cytogen's results to differ materially from those indicated by such forward-looking statements. In particular, Cytogen's business is subject to a n umber of significant risks, which include, but are not limited to: the risk of obtaining the necessary regulatory approvals; the risk of whether products result from development activities; the risk of shifts in the regulatory environment affecting sales of Cytogen's products such as third-party payor reimbursement issues; the risk associated with Cytogen's dependence on its partners for development of certain projects, as well as other factors expressed from time to time in Cytogen's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Cytogen's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Cytogen undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


Cytogen Corporation
Susan M. Mesco, 609-750-8213


Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
3. New Data for Cytogens QUADRAMET Reported at Annual ASCO Meeting
4. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
5. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:11/30/2015)... BOSTON , November 30, 2015 /PRNewswire/ ... potential new medicines directed at up to 10 G ... --> PFE ) to research and develop potential ... receptor (GPCR) targets across multiple therapeutic areas. --> ... discovery and development company and wholly-owned subsidiary of Sosei ...
(Date:11/29/2015)... Nov. 29, 2015  Strengthening its leadership in connected ... PHIA) today announced IntelliSpace Portal 8.0 , the ... visualization platform that helps radiologists detect, diagnose and follow-up ... Radiological Society of North America Annual Meeting (RSNA) ... 8.0 helps address the changing demands in radiology that ...
(Date:11/29/2015)... 2015   National Decision Support Company (NDSC) continues ... including notable statewide implementations. As a result, ordering ... Select, more than 1 million times per month—all ... Select provides real-time feedback on the most appropriate ... been implemented at over 100 healthcare systems nationally, ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... The American ... campaign in honor of World AIDS Day 2015. On Nov. 30, ASCP shared its ... public awareness about World AIDS Day and the importance of getting tested for HIV. ...
(Date:11/30/2015)... ... 30, 2015 , ... According to RF Safe, the November ... at Consumer Reports as supporting a “A Call for Clarity” on cell phone ... original Nov 2015 CR story titled, “Does Cell-Phone Radiation Cause Cancer?” ...
(Date:11/30/2015)... , ... November 30, 2015 , ... While powdered supplements ... in wasted time. Fortunately, an inventor from Chesterfield, Va., has found an easy to ... keep the scoop used to measure powdered contents in a canister or other container ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... suite of automated breast density assessment and enterprise analytics solutions, here at ... 4, 2015 (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable ...
Breaking Medicine News(10 mins):